Advanced

Testing human skin and respiratory sensitizers—what is good enough?

Malmborg, Anki and Borrebaeck, Carl A K LU (2017) In International Journal of Molecular Sciences 18(2).
Abstract

Alternative methods for accurate in vitro assessment of skin and respiratory sensitizers are urgently needed. Sensitization is a complex biological process that cannot be evaluated accurately using single events or biomarkers, since the information content is too restricted in these measurements. On the contrary, if the tremendous information content harbored in DNA/mRNA could be mined, most complex biological processes could be elucidated. Genomic technologies available today, including transcriptional profiling and next generation sequencing, have the power to decipher sensitization, when used in the right context. Thus, a genomic test platform has been developed, denoted the Genomic Allergen Rapid Detection (GARD) assay. Due to the... (More)

Alternative methods for accurate in vitro assessment of skin and respiratory sensitizers are urgently needed. Sensitization is a complex biological process that cannot be evaluated accurately using single events or biomarkers, since the information content is too restricted in these measurements. On the contrary, if the tremendous information content harbored in DNA/mRNA could be mined, most complex biological processes could be elucidated. Genomic technologies available today, including transcriptional profiling and next generation sequencing, have the power to decipher sensitization, when used in the right context. Thus, a genomic test platform has been developed, denoted the Genomic Allergen Rapid Detection (GARD) assay. Due to the high informational content of the GARD test, accurate predictions of both the skin and respiratory sensitizing capacity of chemicals, have been demonstrated. Based on a matured dendritic cell line, acting as a human-like reporter system, information about potency has also been acquired. Consequently, multiparametric diagnostic technologies are disruptive test principles that can change the way in which the next generation of alternative methods are designed.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adverse outcome pathways, Genomics, Next generation in vitro tests, Skin sensitization
in
International Journal of Molecular Sciences
volume
18
issue
2
publisher
MOLECULAR DIVERSITY PRESERVATION INT
external identifiers
  • scopus:85011051963
  • wos:000395457700011
ISSN
1661-6596
DOI
10.3390/ijms18020241
language
English
LU publication?
yes
id
0e3a5806-6dc5-4f77-96e9-2d0461d50c1d
date added to LUP
2017-02-14 11:15:13
date last changed
2018-01-16 13:23:29
@article{0e3a5806-6dc5-4f77-96e9-2d0461d50c1d,
  abstract     = {<p>Alternative methods for accurate in vitro assessment of skin and respiratory sensitizers are urgently needed. Sensitization is a complex biological process that cannot be evaluated accurately using single events or biomarkers, since the information content is too restricted in these measurements. On the contrary, if the tremendous information content harbored in DNA/mRNA could be mined, most complex biological processes could be elucidated. Genomic technologies available today, including transcriptional profiling and next generation sequencing, have the power to decipher sensitization, when used in the right context. Thus, a genomic test platform has been developed, denoted the Genomic Allergen Rapid Detection (GARD) assay. Due to the high informational content of the GARD test, accurate predictions of both the skin and respiratory sensitizing capacity of chemicals, have been demonstrated. Based on a matured dendritic cell line, acting as a human-like reporter system, information about potency has also been acquired. Consequently, multiparametric diagnostic technologies are disruptive test principles that can change the way in which the next generation of alternative methods are designed.</p>},
  articleno    = {241},
  author       = {Malmborg, Anki and Borrebaeck, Carl A K},
  issn         = {1661-6596},
  keyword      = {Adverse outcome pathways,Genomics,Next generation in vitro tests,Skin sensitization},
  language     = {eng},
  month        = {02},
  number       = {2},
  publisher    = {MOLECULAR DIVERSITY PRESERVATION INT},
  series       = {International Journal of Molecular Sciences},
  title        = {Testing human skin and respiratory sensitizers—what is good enough?},
  url          = {http://dx.doi.org/10.3390/ijms18020241},
  volume       = {18},
  year         = {2017},
}